COMPOUND WITH CONFIDENCE: PCCA Membership, $895/month.

Notice

Our blog search feature is temporarily unavailable while we work to resolve an issue. We apologize for the inconvenience and appreciate your patience. We’ll restore it as soon as possible.

Pharmacy compounding's source for clinical information, regulatory updates, and opportunities

THE PCCA BLOG

rss

Stay current on PCCA news and events, market trends, and all things compounding!

Working_with_Compounders_The_FDAs_Recent_Statement_about_Oxitriptan.png

Working with Compounders: The FDA’s Recent Statement about Oxitriptan

PCCA applauds the FDA for their decision and statement about Oxitriptan, which ensures that patients with BH4 deficiency can continue to receive the compounded medications they need.

Read More